Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance
Open Access
- 21 October 2021
- journal article
- editorial
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (39), 6515-6521
- https://doi.org/10.3748/wjg.v27.i39.6515
Abstract
In this editorial, we comment on pancreatic cancer (PC), one of the most aggressive and lethal cancers. Only minimal improvements in survival rates have been achieved over recent years. Available chemotherapeutic regimens have little impact, and surgical resection remains the only reliable curative approach. We address current treatment options for these patients, focusing on the usefulness of breast cancer (BRCA) gene mutation as a prognostic biomarker and predictor of response to chemotherapy. Superior survival outcomes have been reported in patients with PC and mutant BRCA gene treated with first-line platinum-based chemotherapy. Therefore, it appears appropriate to include BRCA gene status among clinical criteria used to select the chemotherapy regimen. In addition, maintenance treatment with poly(ADP-ribose) polymerase inhibitors has been found to improve progression-free survival in patients with PC and mutated BRCA whose disease does not progress after first-line platinum-based chemo therapy. This combination has therefore been proposed as the optimal treatment regimen for these patients.Keywords
This publication has 36 references indexed in Scilit:
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionClinical Cancer Research, 2017
- PARP inhibitors: Synthetic lethality in the clinicScience, 2017
- Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in SpainClinical and Translational Oncology, 2016
- Pancreatic cancer: BRCA mutation and personalized treatmentExpert Review of Anticancer Therapy, 2015
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersBritish Journal of Cancer, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future DirectionsThe Oncologist, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Genome maintenance mechanisms for preventing cancerNature, 2001